Timber Pharmaceuticals to Present at the LD Micro 500 Virtual Conference
Timber Pharmaceuticals (NYSE American: TMBR), a biopharmaceutical company specializing in orphan dermatologic diseases, will present at the LD Micro 500 virtual investor conference on September 2, 2020, at 10:20am ET. CEO John Koconis will lead the presentation, which will be followed by one-on-one meetings with investors. The event runs from September 1-4, 2020. Interested parties can access the live webcast and replay through a provided link. Timber is focused on developing treatments for conditions like congenital ichthyosis and localized scleroderma.
- None.
- None.
LOS ANGELES, CA / ACCESSWIRE / August 27, 2020 / Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE American:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced that it will be presenting at the LD Micro 500 virtual investor conference on Wednesday, September 2, 2020 at 10:20am ET. John Koconis, Chief Executive Officer of Timber, will be presenting to a live audience and will be available for virtual one-on-one meetings with investors throughout the conference.
The online presentation will be webcast live and available for replay by following this link: https://www.webcaster4.com/Webcast/Page/2019/36151
The LD Micro 500 will be held September 1-4, 2020. Interested investors should contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information or can register at this link: https://ld-micro-conference.events.issuerdirect.com/
View Timber Pharmaceutical's profile here: http://www.ldmicro.com/profile/TMBR.
Profiles powered by LD Micro - News Compliments of Accesswire
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and localized scleroderma. For more information, visit www.timberpharma.com.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LD Micro launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD Micro will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.
For more information, contact:
Timber Pharmaceuticals, Inc.
John Koconis
Chief Executive Officer
jkoconis@timberpharma.com
Investor Relations:
Stephanie Prince
PCG Advisory
(646) 762-4518
sprince@pcgadvisory.com
Media Relations:
Adam Daley
Berry & Company Public Relations
(212) 253-8881
adaley@berrypr.com
SOURCE: Timber Pharmaceuticals via LD Micro
View source version on accesswire.com:
https://www.accesswire.com/603541/Timber-Pharmaceuticals-to-Present-at-the-LD-Micro-500-Virtual-Conference
FAQ
When is Timber Pharmaceuticals presenting at the LD Micro 500 conference?
What is the focus of Timber Pharmaceuticals?
How can I watch the Timber Pharmaceuticals presentation at the LD Micro conference?
What diseases is Timber Pharmaceuticals targeting with its treatments?
Who is presenting on behalf of Timber Pharmaceuticals at the LD Micro 500?
